Inspired by biology, perfected with pharmacology

Our proprietary platform ensures consistent purity and potency of DMT and harmala compounds through scalable pharmaceutical manufacturing. By overcoming the variability, sourcing challenges, and regulatory barriers of traditional botanical medicines, we are advancing precision bioequivalent neuromedicines designed for clinical applications

Groundbreaking Progress In DMT and Harmala Chemistry

We've successfully completed the world's first clinical study of a precisely standardised, pharmaceutically manufactured DMT and multi-harmala formulation, demonstrating robust effects and a favourable safety profile.

How It Works

We are developing synergistic formulations of DMT and harmala alkaloids, optimising active compound selection, doses, ratios, and delivery routes to precisely target neurobiological pathways and therapeutic needs across diverse neuropsychiatric conditions.

Learn More About Our Compounds

DMT

DMT (N,N-Dimethyltryptamine) is a naturally occurring tryptamine that modulates multiple receptor systems, including serotonin (5-HT2A and others) and sigma-1 receptors. It promotes emotional processing, cognitive flexibility, and neuroplasticity, and demonstrates strong potential as a rapid-acting therapeutic agent for neuropsychiatric conditions.

Harmala Alkaloids

Harmala alkaloids are naturally occurring monoamine oxidase inhibitors that enhance the bioavailability of DMT and raise serotonin and norepinephrine levels. They also activate neural pathways involved in emotional regulation and neuroplasticity, and have demonstrated antidepressant and anti-addictive effects.

Our Pipeline

Our pipeline maximises therapeutic and commercial potential across psychiatric, addictive and neurological disorders. Our drug candidates contain unique active compounds, doses, ratios, and delivery routes. In addition, we are advancing differentiated products spanning high-dose psychedelic, rapid-onset, and sub-perceptual profiles. This strategy enables flexible targeting of acute and chronic conditions across a broad range of market segments.